Insider Transactions in Q1 2022 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.29%
|
$4,018
$49.28 P/Share
|
|
Mar 15
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.32%
|
$14,625
$39.57 P/Share
|
|
Mar 15
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+5.65%
|
$28,000
$4.31 P/Share
|
|
Mar 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.48%
|
$48,750
$39.57 P/Share
|
|
Mar 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.48%
|
$2,500
$2.67 P/Share
|
|
Mar 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.34%
|
$16,125
$43.53 P/Share
|
|
Feb 23
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+3.59%
|
$16,400
$4.31 P/Share
|
|
Feb 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.19%
|
$56,250
$45.43 P/Share
|
|
Feb 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.18%
|
$2,500
$2.67 P/Share
|
|
Feb 15
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.35%
|
$16,875
$45.43 P/Share
|
|
Feb 14
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
720
+1.36%
|
$18,720
$26.73 P/Share
|
|
Feb 14
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,600
+3.27%
|
$14,400
$4.31 P/Share
|
|
Feb 11
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,666
-3.13%
|
$76,636
$46.8 P/Share
|
|
Feb 10
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,901
+14.68%
|
-
|
|
Feb 10
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-1.14%
|
$12,737
$47.12 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-15.83%
|
$500,000
$50.0 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.67%
|
$130,000
$13.85 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-1.26%
|
$31,866
$47.12 P/Share
|
|
Feb 10
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-0.61%
|
$8,225
$47.12 P/Share
|
|
Feb 10
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
875
-0.84%
|
$41,125
$47.12 P/Share
|
|
Feb 10
2022
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
705
-0.68%
|
$33,135
$47.12 P/Share
|
|
Feb 10
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-1.99%
|
$42,065
$47.12 P/Share
|
|
Feb 10
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,057
-0.12%
|
$49,679
$47.12 P/Share
|
|
Feb 10
2022
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,523
-0.26%
|
$118,581
$47.12 P/Share
|
|
Feb 10
2022
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-0.37%
|
$23,077
$47.12 P/Share
|
|
Feb 08
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-15.66%
|
$450,000
$45.0 P/Share
|
|
Feb 08
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.54%
|
$130,000
$13.85 P/Share
|
|
Feb 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.36%
|
$15,000
$40.58 P/Share
|
|
Jan 31
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,233
-2.24%
|
$46,854
$38.47 P/Share
|
|
Jan 28
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
642
-1.15%
|
$24,396
$38.59 P/Share
|
|
Jan 28
2022
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.82%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,024
-0.15%
|
$76,912
$38.59 P/Share
|
|
Jan 28
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
931
-0.1%
|
$35,378
$38.59 P/Share
|
|
Jan 28
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-1.75%
|
$30,400
$38.59 P/Share
|
|
Jan 28
2022
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.49%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.62%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-1.8%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.62%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.3%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-2.07%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.5%
|
$16,492
$38.59 P/Share
|
|
Jan 21
2022
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,974
+31.09%
|
-
|
|
Jan 21
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,592
+33.57%
|
-
|
|
Jan 21
2022
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
17,466
+37.58%
|
-
|
|
Jan 21
2022
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,466
+42.21%
|
-
|
|
Jan 21
2022
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+16.32%
|
-
|
|
Jan 21
2022
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+43.8%
|
-
|
|
Jan 21
2022
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+41.85%
|
-
|
|
Jan 21
2022
|
Federico Grossi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+19.94%
|
-
|
|
Jan 21
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+36.3%
|
-
|